Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

WCLC Updates on the Emergence of ADCs in NSCLC

February 26th 2021

Panelists provide insight into emerging clinical trial data on antibody-drug conjugates (ADCs) presented at the IASLC 2020 World Conference on Lung Cancer (WCLC).

WCLC Updates in KRAS and Rare EGFR-Mutated NSCLC

February 26th 2021

Experts in thoracic oncology review data presented at the IASLC 2020 World Conference on Lung Cancer (WCLC) and discuss safety and efficacy of targeted agents for patients with KRAS- or EGFR-mutated non–small cell lung cancer (NSCLC).

Dr. Heymach on the Efficacy of Mobocertinib in EGFR Exon 20 Insertion–Mutated NSCLC

February 25th 2021

John V. Heymach, MD, PhD, discusses the efficacy of mobocertinib in EGFR exon 20 insertion–mutated advanced non–small cell lung cancer.

FDA Grants Breakthrough Therapy Designation to Cabozantinib for Radioactive Iodine–Refractory Differentiated Thyroid Cancer

February 25th 2021

The FDA has granted a breakthrough therapy designation to cabozantinib as a potential therapeutic option for patients with differentiated thyroid cancer that has progressed after previous therapy and who are refractory to radioactive iodine.

Dr. Majem on the Safety Profile of Osimertinib in EGFR+ NSCLC

February 24th 2021

Margarita Majem, MD, PhD, discusses the safety profile of osimertinib in patients with EGFR-mutated non–small cell lung cancer.

Dr. Li on the Efficacy of Sotorasib in KRAS+ Advanced NSCLC

February 24th 2021

Bob T. Li, MD, PhD, MPH, discusses the efficacy of sotorasib in patients with KRAS G12C–mutated advanced non-small cell lung cancer, as demonstrated in phase 2 cohort results of the phase 2 CodeBreaK 100 trial.

Dr. Heymach on the Potential Utility of Afatinib in NRG1 Fusion+ NSCLC

February 23rd 2021

John V. Heymach, MD, PhD, discusses the potential utility of afatinib in NRG1 fusion–positive non–small cell lung cancer.

FDA Approves Companion Diagnostic for Cemiplimab in NSCLC

February 23rd 2021

February 23, 2021 - The FDA has approved the PD-L1 IHC 22C3 pharmDx assay, developed by Agilent Technologies Inc, for expanded use in patients with non–small cell lung cancer.

Investigators Aim Novel T-Cell Therapy at Solid Tumor Target

February 23rd 2021

ADP-A2M4CD8, a novel T-cell therapy, is being investigated in a range of tumor types that express MAGEA4, an antigen expressed in solid tumors that investigators say represents a promising target for cellular immunotherapy.

FDA Approves Cemiplimab for Frontline Advanced NSCLC With High PD-L1 Expression

February 22nd 2021

February 22, 2021 - The FDA has approved cemiplimab-rwlc monotherapy for use in the frontline treatment of patients with advanced non–small cell lung cancer with a PD-L1 expression level of 50% or higher.

Immunotherapy Keeps Impressing in Advanced NSCLC, With Improvements on the Horizon

February 22nd 2021

Davey B. Daniel, MD, discusses key immunotherapy trials in advanced non–small cell lung cancer and explains how the results can be extrapolated to clinical practice.

Dr. Piotrowska on the Utility of Mobocertinib in EGFR Exon 20–Mutant NSCLC

February 19th 2021

Zofia Piotrowska, MD, MHS, discusses the utility of mobocertinib in patients with non–small cell lung cancer who harbor EGFR exon 20 insertions.

Rapid Readouts: Postoperative Chemotherapy Use and Outcomes from ADAURA

February 19th 2021

Roy S. Herbst, MD, PhD, presents slides from the IASLC 2020 World Conference on Lung Cancer for postoperative chemotherapy use and outcomes from the phase 3 ADAURA trial of osimertinib as adjuvant therapy in patients with resected EGFR mutated NSCLC.

Rapid Readouts: Patient-Reported Outcomes from ADAURA

February 19th 2021

Roy S. Herbst, MD, PhD, presents slides from the IASLC 2020 World Conference on Lung Cancer for patient-reported outcomes from the phase 3 ADAURA trial of osimertinib as adjuvant therapy in patients with resected EGFR mutated NSCLC.

Dr. Shu on the MOA of Amivantamab in EGFR Exon 20 Insertion–Mutated NSCLC

February 19th 2021

Catherine Ann Shu, MD, discusses the mechanism of action of amivantamab in patients with EGFR exon 20 insertion–mutated non–small cell lung cancer.

Rodriguez Relays Insight Into the Integration of Immunotherapy in Lung Cancer

February 18th 2021

In our exclusive interview, Dr. Rodriguez discusses historic treatments in lung cancer that preceded the integration of immunotherapy, shares current treatment selection and sequencing strategies, and forecasts the future of immunotherapy in the field.

Cemiplimab Significantly Improves Survival in Advanced NSCLC With PD-L1 of at Least 50%

February 18th 2021

February 18, 2021 - Single-agent cemiplimab has been found to result in a significant improvement in overall survival and progression-free survival versus chemotherapy in patients with advanced non–small cell lung cancer who had a PD-L1 expression of at least 50%.

Bad Company: Concurrent Mutations Define Unique Subsets of NSCLC

February 18th 2021

The identification of oncogenic driver mutations in non–small cell lung cancer to inform targeted therapy selection is the bedrock of clinical practice in this disease, with current estimates suggesting that more than half of patients harbor an actionable mutation.

Dr. Liu on the Rationale for Examining Afatinib in NSCLC Harboring NRG1 Fusions

February 17th 2021

Stephen Liu, MD, discusses the rationale for examining afatinib in patients with non–small cell lung cancer harboring NRG1 fusions.

FDA Grants Priority Review to Sotorasib for KRAS G12C–Mutated Advanced or Metastatic NSCLC

February 17th 2021

February 16, 2021 - The FDA has granted priority review to sotorasib for the treatment of patients with KRAS G12C–mutated locally advanced or metastatic non–small cell lung cancer, after at least 1 previous systemic therapy